ONCY: Oncolytics Year-over-year earnings per share growth for the last twelve months

Public company logo of Oncolytics (ONCY)

Dependence on the Pelareorep platform and B2B contracts creates risks that are evident in the quarterly EPS growth. The value of 22.50 shows the current magnitude of this metric. Geopolitical barriers limit technology exports and patient access, while the automation of incubation in sterile zones minimizes personnel errors, strengthening the operational base of Oncolytics Biotech Inc. (ONCY).

Oncolytics Biotech, Inc. (ONCY) - Quarterly EPS earnings growth from 07/04/2022 to 11/15/2026

Analytical breakdowns for Oncolytics Biotech (ONCY)

- market value and analyst target forecast:
Price Chart Oncolytics Biotech|ONCY - Forecast Levels Chart
- market capitalization information:
Market Value Oncolytics Biotech|ONCY - Total Company Value
- book capitalization data:
Book Value per Share Oncolytics Biotech|ONCY - Book Capitalization|Market Cap to Net Assets Ratio oncolyticsbiotech.com|ONCY - Aggregate Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital Oncolytics Biotech Inc.|ONCY - Long-Term Liabilities to Equity|Short-Term Debt to Equity oncolyticsbiotech.com|ONCY - Company Cumulative Debt|Debt to Book Capitalization Ratio Oncolytics Biotech Inc.|ONCY - Company Long-Term Loans and Borrowings|Company Short-Term Debt Oncolytics Biotech|Quick Liquidity oncolyticsbiotech.com
- earnings and valuation multiples indicators:
ONCY - Net Financial Result|Expected Profit Oncolytics Biotech Inc.|ONCY - Market Cap to Earnings|Future Price to Earnings Oncolytics Biotech Inc.|ONCY - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Oncolytics Biotech Inc.|ONCY - Operating profit before deduction of amortization|Earnings per share for the last twelve months Oncolytics Biotech|ONCY - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months oncolyticsbiotech.com|ONCY - Earnings per share growth in current year|Expected earnings per share growth for next year Oncolytics Biotech Inc.
- revenue and sales details:
ONCY - Company Total Revenue|Company Future Sales Volume oncolyticsbiotech.com|ONCY - Market Cap to Sales Volume|Forward P/S Multiple Oncolytics Biotech, Inc.|ONCY - Annual Revenue Growth (Last Twelve Months)
Comprehensive company analysis:Oncolytics Biotech Inc.
Flagship merchandise of oncolyticsbiotech.com

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. Positive momentum signals efficient capital management, whereas a decline indicates increasing losses. By analyzing a snapshot of quarterly EPS dynamics, an investor assesses the rate of change in financial results. For Oncolytics Biotech Inc. (ONCY), this metric reflects only the cash burn rate. The absence of revenue makes this metric a derivative of external financing and the success of clinical trials.

Who Oncolytics Biotech Inc. competes with

Geron (GERN) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months NBTX (Nanobiotix Group)|Year-over-year earnings per share growth for the last twelve months Bicycle Therapeutics|Year-over-year earnings per share growth for the last twelve months CTMX|Quarterly EPS earnings growth CATX|Quarterly EPS earnings growth Genelux Corp (GNLX)|Molecular Partners AG - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months LSTA (Lisata)|Moleculin Biotech, Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months GRTX|Molecular Templates Corporation (MTEM) - Year-over-year earnings per share growth for the last twelve months